Axoft

Axoft is pursuing a materials-first approach to invasive BCIs: make the implant extremely soft (closer to brain tissue mechanics) so the interface causes less chronic irritation, scarring, and drift.

The core claim is straightforward:

• conventional implant materials are mechanically mismatched with brain tissue
• micromotion + foreign-body response degrade long-term signal quality
• a brain-like polymer could improve long-term stability

What they’re building (public description)

Axoft describes a full stack:

• a bioinspired soft implant (ultra-soft material)

• integrated electronics + wireless data path

• surgical tools to place very soft probes without using the probe itself as the rigid inserter

• decoding software

• Axoft homepage: ⁰¹

Human/clinical status (public reporting)

Axoft announced approval for a first-in-human clinical study planned for early 2025 at The Panama Clinic. Public reporting describes the study as testing insertion + recording feasibility during already-planned resection surgeries.

• BioSpace/BusinessWire repost (Dec 19, 2024): ⁰²
• Medical Device Network summary (Dec 20, 2024): ⁰³

• Clinical: the same announcement period reported a temporary implant of its soft probe in a patient in Shanghai (secondary: ⁰⁴). The Panama study described above was “planned” status as of Dec 2024.

Why this is interesting

If Axoft’s mechanical matching actually translates into:

• lower glial scarring / neuron loss near the interface
• lower drift
• stable single-unit recordings over long timescales

…then it’s a direct shot at one of the hardest real problems in invasive BCI: maintaining usable signals for years.

Company background

• Location corrected: Axoft is based in Cambridge, Massachusetts (148 Sidney St), not Detroit. Source: ⁰⁵

• Funding (Apr 29, 2026): Axoft announced an oversubscribed $55M Series A led by C.P. Group Innovation to advance clinical trials globally. Source: ⁰⁶

What to watch

1. Signal stability vs time (weeks → months → years)
2. Surgical workflow for very soft probes (tooling, reliability, placement repeatability)
3. Failure modes (buckling, delamination, encapsulation, connector issues)
4. Actual clinical indication path (what’s the first medical use case, and how does it win vs existing implants?)